The Food and Drug Administration (FDA), led by Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), is tirelessly and relentlessly promoting continuous manufacturing (CM) as the best opportunity to achieve its 21st Century Quality vision "...a maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drugs without extensive regulatory oversight."

To read more go to http://digital.pharmpro.com/pharmaceuticalproducts/ips_interphex_tour_april_2016?pg=16#pg16